 This study will be a prospective randomized trial. Thirty subjects with mild to moderate asthma will receive inhaled fluticasone propionate. Fifteen patients will receive low dose inhaled fluticasone 88 mcg twice daily. Fifteen patients will receive inhaled fluticasone 440 mcg twice daily. The primary outcome will be biochemical markers of bone turnover. These will include 1 serum biochemical markers of bone formation osteocalcin, bone specific alkaline phosphatase ALP and procollagen I C-terminal propeptide PICP and 2 markers of bone resorption, serum collagen type 1 C-Telopeptide CTx urinary N-telopeptide NTx and immunoreactive free deoxypyridinoline iFDpd. Secondary endpoints will include, parathyroid hormone PTH, Urinary Calciumcreatinine, and adverse events. 